Zacks: Analysts Expect Spectrum Pharmaceuticals, Inc. (SPPI) Will Announce Quarterly Sales of $34.40 Million

Brokerages expect Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to report sales of $34.40 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Spectrum Pharmaceuticals’ earnings. The highest sales estimate is $34.50 million and the lowest is $34.30 million. Spectrum Pharmaceuticals posted sales of $33.39 million during the same quarter last year, which suggests a positive year over year growth rate of 3%. The company is scheduled to report its next quarterly earnings results on Monday, November 13th.

On average, analysts expect that Spectrum Pharmaceuticals will report full-year sales of $34.40 million for the current fiscal year, with estimates ranging from $133.00 million to $133.60 million. For the next fiscal year, analysts anticipate that the firm will post sales of $134.00 million per share, with estimates ranging from $126.20 million to $141.80 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Spectrum Pharmaceuticals.

Spectrum Pharmaceuticals (NASDAQ:SPPI) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.01. Spectrum Pharmaceuticals had a negative net margin of 59.33% and a negative return on equity of 30.95%. The business had revenue of $34.30 million for the quarter, compared to analysts’ expectations of $30.50 million. During the same period in the prior year, the company posted ($0.35) EPS. The business’s revenue for the quarter was up 1.0% compared to the same quarter last year.

A number of equities analysts have weighed in on SPPI shares. Jefferies Group LLC set a $9.00 price target on shares of Spectrum Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 25th. Zacks Investment Research upgraded shares of Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. ValuEngine upgraded shares of Spectrum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, May 11th. HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of Spectrum Pharmaceuticals in a research report on Wednesday, August 16th. Finally, BidaskClub lowered shares of Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $10.80.

Several large investors have recently modified their holdings of the stock. Piedmont Investment Advisors LLC bought a new position in shares of Spectrum Pharmaceuticals during the second quarter worth $114,000. State Street Corp boosted its position in shares of Spectrum Pharmaceuticals by 28.3% during the second quarter. State Street Corp now owns 3,020,563 shares of the biotechnology company’s stock worth $22,507,000 after acquiring an additional 666,605 shares during the last quarter. Cornerstone Capital Management Holdings LLC. boosted its position in shares of Spectrum Pharmaceuticals by 196.5% during the second quarter. Cornerstone Capital Management Holdings LLC. now owns 187,697 shares of the biotechnology company’s stock worth $1,397,000 after acquiring an additional 124,383 shares during the last quarter. Macquarie Group Ltd. boosted its position in shares of Spectrum Pharmaceuticals by 9.4% during the second quarter. Macquarie Group Ltd. now owns 2,247,493 shares of the biotechnology company’s stock worth $16,744,000 after acquiring an additional 193,883 shares during the last quarter. Finally, PDT Partners LLC boosted its position in shares of Spectrum Pharmaceuticals by 15.3% during the second quarter. PDT Partners LLC now owns 142,000 shares of the biotechnology company’s stock worth $1,058,000 after acquiring an additional 18,800 shares during the last quarter. Hedge funds and other institutional investors own 66.09% of the company’s stock.

Spectrum Pharmaceuticals (NASDAQ:SPPI) traded up 1.23% during mid-day trading on Friday, hitting $9.88. 713,934 shares of the stock traded hands. The company’s market cap is $776.33 million. Spectrum Pharmaceuticals has a 12 month low of $3.21 and a 12 month high of $9.96. The company’s 50 day moving average is $8.66 and its 200 day moving average is $7.08.

ILLEGAL ACTIVITY WARNING: This piece was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/09/04/zacks-analysts-expect-spectrum-pharmaceuticals-inc-sppi-will-announce-quarterly-sales-of-34-40-million.html.

Spectrum Pharmaceuticals Company Profile

Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).

Get a free copy of the Zacks research report on Spectrum Pharmaceuticals (SPPI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spectrum Pharmaceuticals (NASDAQ:SPPI)

Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply